The combination of the companies aims to create a clinical trial technology platform differentiated by its ability to conduct paperless clinical trials.
Clinical Ink also announced that MPM Capital and F2 Ventures joined FCA Venture Partners and other existing investors to provide additional growth capital for Clinical Ink to expand operational capabilities and further develop this paperless clinical trial platform.
Through the use of CentrosHealth and Clinical Ink’s tools, research sponsors can receive all of their data, both from the site and the patient, in real-time, which can reduce the cost, time, and complexity of the trial process. The Clinical Ink approach to eSource and mobile data capture has been endorsed by both FDA and EMA, the company claims, as it’s a component of risk-based monitoring approaches to clinical research oversight.
Jeremy Sohn, Founder/CEO of CentrosHealth, said: “Our platform seamlessly integrates clinical trial activities such as medication reminders, visit scheduling, activity measurements and ePRO into patients’ every-day life through personalized notifications, text messages, calendar integration, and a highly functional mobile application on their personal cellphone.”
Novartis Deal
In addition to the merger, Clinical Ink entered into a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to help drive industry-wide adoption of fully electronic clinical trials.
Ed Seguine, CEO of Clinical Ink, said: “The involvement of Novartis is a significant validation of our pioneering efforts to create a completely paperless clinical trial platform and to reduce the cost, time and complexity of clinical research.”